WATCH TV LIVE

Brain Cancer Drug Shows Effectiveness in Trial

Wednesday, 25 March 2015 12:35 PM EDT

Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival.

The drug developer's shares were up 20 percent at $6.70 in premarket trade on Wednesday.

The company said its drug, VBL-111, significantly improved overall survival when used in combination with Roche AG's cancer treatment, Avastin.

The company said it stopped testing the drug as a monotherapy after the disease progressed in nearly half the patients in the study who were given only VBL-111.

VBL is also testing VBL-111 as a treatment for thyroid cancer and ovarian cancer.

Click Here to comment on this article

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

Yes, Send Me News Alerts via email

(Optional for Local News)

Privacy: We never share your email address.

Join the Newsmax Community

Read and Post Comments
Please review Community Guidelines before posting a comment.

Find Your Condition

Cancer	Heart Disease
Obesity	Arthritis
Alzheimer's/Dementia	Digestive Problems
Cold/Flu	Depression
Allergies	High Cholesterol
Chronic Pain	Thyroid Disorders
Menopause	Osteoporosis
Autism	Anxiety
High Blood Pressure	Diabetes

More Conditions

TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.